Fractyl Health (NASDAQ:GUTS) Releases Earnings Results, Misses Expectations By $0.01 EPS

Fractyl Health (NASDAQ:GUTS) announced its quarterly earnings data on Wednesday. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01), Zacks reports.

Fractyl Health Stock Down 0.9%

Shares of GUTS opened at $1.12 on Friday. The company has a debt-to-equity ratio of 4.61, a current ratio of 1.22 and a quick ratio of 1.22. The stock has a market capitalization of $56.32 million, a price-to-earnings ratio of -0.49 and a beta of 2.20. Fractyl Health has a 1 year low of $0.83 and a 1 year high of $3.03. The business’s 50 day simple moving average is $1.21 and its 200-day simple moving average is $1.46.

Hedge Funds Weigh In On Fractyl Health

Several institutional investors have recently bought and sold shares of GUTS. Jane Street Group LLC purchased a new stake in shares of Fractyl Health during the 2nd quarter valued at about $31,000. JPMorgan Chase & Co. purchased a new stake in Fractyl Health during the third quarter valued at approximately $81,000. Osaic Holdings Inc. lifted its stake in shares of Fractyl Health by 460.3% in the 2nd quarter. Osaic Holdings Inc. now owns 59,645 shares of the company’s stock valued at $97,000 after purchasing an additional 49,000 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in shares of Fractyl Health in the 2nd quarter worth approximately $129,000. Finally, Woodline Partners LP increased its position in shares of Fractyl Health by 47.2% during the 1st quarter. Woodline Partners LP now owns 516,921 shares of the company’s stock valued at $615,000 after purchasing an additional 165,786 shares during the last quarter.

Wall Street Analyst Weigh In

GUTS has been the topic of several research analyst reports. HC Wainwright lowered their price objective on Fractyl Health from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, September 26th. Canaccord Genuity Group lowered their price target on Fractyl Health from $12.00 to $6.00 and set a “buy” rating on the stock in a report on Thursday, August 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Fractyl Health in a research note on Wednesday, October 8th. Finally, LADENBURG THALM/SH SH initiated coverage on shares of Fractyl Health in a report on Thursday, August 28th. They set a “buy” rating and a $3.60 price objective for the company. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.90.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.